These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 2977394)

  • 1. The effects of renal function on the disposition of isradipine.
    Chandler MH; Schran HF; Cutler RE; Smith AJ; Gonasun LM; Blouin RA
    J Clin Pharmacol; 1988 Dec; 28(12):1076-80. PubMed ID: 2977394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics of oral isradipine in normal volunteers.
    Clifton GD; Blouin RA; Dilea C; Schran HF; Hassell AE; Gonasun LM; Foster TS
    J Clin Pharmacol; 1988 Jan; 28(1):36-42. PubMed ID: 2965165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploratory analysis of population pharmacokinetic data from clinical trials with application to isradipine.
    Laplanche R; Fertil B; Nüesch E; Jais JP; Niederberger W; Steimer JL
    Clin Pharmacol Ther; 1991 Jul; 50(1):39-54. PubMed ID: 1830252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
    Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ
    Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intragastric behavior and absorption kinetics of a normal and "floating" modified-release capsule of isradipine under fasted and fed conditions.
    Mazer N; Abisch E; Gfeller JC; Laplanche R; Bauerfeind P; Cucala M; Lukachich M; Blum A
    J Pharm Sci; 1988 Aug; 77(8):647-57. PubMed ID: 2974884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
    Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition and safety of omapatrilat in subjects with renal impairment.
    Sica DA; Liao W; Gehr TW; Khan S; Jemal M; Delaney CL; Ferreira IM; Malhotra BK
    Clin Pharmacol Ther; 2000 Sep; 68(3):261-9. PubMed ID: 11014407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and dialysability of isradipine in chronic haemodialysis patients.
    Schönholzer K; Marone C
    Eur J Clin Pharmacol; 1992; 42(2):231-3. PubMed ID: 1535593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of verapamil and isradipine on steady-state digoxin kinetics.
    Rodin SM; Johnson BF; Wilson J; Ritchie P; Johnson J
    Clin Pharmacol Ther; 1988 Jun; 43(6):668-72. PubMed ID: 2967742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension.
    Petersen LJ; Petersen JR; Talleruphuus U; Møller ML; Ladefoged SD; Mehlsen J; Jensen HA
    Clin Nephrol; 2001 May; 55(5):375-83. PubMed ID: 11393383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of isradipine on blood pressure and renal function.
    Pedersen OL; Krusell LR; Sihm I; Jespersen LT; Thomsen K
    Am J Med; 1989 Apr; 86(4A):15-8. PubMed ID: 2523650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.
    Sobue S; Tan K; Layton G; Leclerc V; Weil A
    Br J Clin Pharmacol; 2004 Jun; 57(6):773-84. PubMed ID: 15151523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal effects of the new calcium channel blocking drug isradipine.
    Krämer BK; Häussler M; Ress KM; Müller GA; Burger KJ; Risler T
    Eur J Clin Pharmacol; 1990; 39(4):333-5. PubMed ID: 2150190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repetitive natriuresis and blood pressure. Long-term calcium entry blockade with isradipine.
    Krusell LR; Jespersen LT; Schmitz A; Thomsen K; Pedersen OL
    Hypertension; 1987 Dec; 10(6):577-81. PubMed ID: 2447016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.
    Muirhead GJ; Wilner K; Colburn W; Haug-Pihale G; Rouviex B
    Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):21S-30S. PubMed ID: 11879256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmokinetics of isradipine in hypertensive subjects.
    Shenfield GM; Boutagy J; Stokes GS; Rumble F; Dunagan F
    Eur J Clin Pharmacol; 1990; 38(2):209-11. PubMed ID: 2140098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of loratadine in patients with renal insufficiency.
    Matzke GR; Halstenson CE; Opsahl JA; Hilbert J; Perentesis G; Radwanski E; Zampaglione N
    J Clin Pharmacol; 1990 Apr; 30(4):364-71. PubMed ID: 2140371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir.
    Cass LM; Efthymiopoulos C; Marsh J; Bye A
    Clin Pharmacokinet; 1999; 36 Suppl 1():13-9. PubMed ID: 10429836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term antihypertensive and renal effects of isradipine in hypertensive patients with normal and reduced renal function.
    Wittenberg C; Rosenfeld JB
    J Cardiovasc Pharmacol; 1992; 19 Suppl 3():S93-5. PubMed ID: 1376848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability of isradipine in young and old rats: effect of mode of administration.
    Tse FL; Jaffe JM; Hassell AE; Schran HF
    J Pharm Pharmacol; 1989 Sep; 41(9):657-60. PubMed ID: 2573717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.